GlassScriptPhysician profile
Subba R Gollamudi
NPI 1154378735
$67,249.17
in general payments reported to CMS, 2019-2025
33 companies · $2,958 in 2025
The $2,958 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $2,826 · 2021: $20K · 2022: $14K · 2023: $1,988 · 2024: $3,619 · 2025: $2,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,480 · Education: $60.00 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,480.22 |
| Education | $60.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $37,447.73 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11,575.72 | 2019-2021 | |
| Eyepoint US, INC. | $2,957.08 | 2019-2021 | |
| Alcon Vision LLC | $2,576.32 | 2019-2025 | Clareon, Lensx, Clareon Panoptix Pro |
| Ocular Therapeutix, INC. | $1,988.45 | 2019-2024 | Dextenza |
| Glaukos Corporation | $1,963.24 | 2020-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Sun Pharmaceutical Industries INC. | $1,651.00 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $1,035.60 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Xiidra |
| Mallinckrodt Hospital Products INC. | $891.54 | 2020-2025 | Acthar |
| Kala Pharmaceuticals, INC. | $799.37 | 2019-2021 | |
| Harrow Eye, LLC | $788.82 | 2023-2025 | Vevye, Iheezo |
| Abbvie INC. | $571.35 | 2022-2025 | |
| Biotissue Holdings INC. | $511.12 | 2021-2025 | |
| Rxsight INC | $463.33 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Novartis Pharmaceuticals Corporation | $357.94 | 2019-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $208.85 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $194.94 | 2019-2022 | |
| Dompe US, INC. | $155.34 | 2021-2025 | Oxervate |
| New World Medical,INC. | $143.37 | 2021-2022 | |
| Horizon Therapeutics Plc | $139.51 | 2022-2023 | Tepezza |
| Amgen INC. | $131.12 | 2024-2025 | Tepezza |
| Thea Pharma INC. | $127.06 | 2025 | Iyuzeh |
| Johnson & Johnson Vision Care, INC. | $86.76 | 2019 | |
| Oyster Point Pharma, INC. | $83.96 | 2022-2024 | Tyrvaya |
| Dutch Ophthalmic, USA | $83.02 | 2019 | |
| Ani Pharmaceuticals, INC. | $72.11 | 2024-2025 | Purified Cortrophin Gel |
| Notal Vision, INC. | $53.89 | 2021 | |
| Aerie Pharmaceuticals, INC. | $50.34 | 2021 | |
| Shire North American Group INC | $46.89 | 2019 | |
| Carl Zeiss Meditec, INC. | $43.29 | 2021 | |
| Rayner Intraocular Lenses Limited | $20.65 | 2024 | Rayone Spheric, Rayone Emv, Omidria |
| Tarsus Pharmaceuticals, INC. | $18.28 | 2024 | Xdemvy |
| Omeros Corporation | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subba Gollamudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.